Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?

Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.